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percentage of CAP patients who were hospitalized was 
45 %, ranging from 12 % (age 18–49, low risk) to 57 % 
(age ≥65, high risk). One-year all-cause mortality rates 
ranged from 1 % (age 18–49, low risk) to 36 % (age ≥65, 
high risk). Annual VHA medical expenditure related to 
CAP was estimated to be $750 million (M) ($415M for 
those aged ≥65 years).
Conclusion A focus on CAP prevention among older Vet-
erans and those with comorbid or immunocompromising 
conditions is important.
Keywords Community-acquired pneumonia · Risk 
status · Risk factor · Burden of disease · Epidemiology · 
Veterans
Introduction
Community-acquired pneumonia (CAP) includes pneumo-
nia transmitted outside of hospitals or extended-care facili-
ties and is one of the most commonly diagnosed infectious 
diseases. There are over 100 pathogens known to cause 
CAP, including bacteria, viruses, and fungi. The most com-
mon bacterial pathogen of CAP is Streptococcus (S.) pneu-
moniae, which accounts for more than a third of all adult 
CAP [1], and has been shown to have mortality rates that 
are three times higher compared to other pathogens [2, 3].
An estimated 4–6 million (M) CAP cases occur annually 
in the United States, of which, roughly 20–25 % require 
hospitalization [4–6]. Overall mortality from CAP ranges 
5–30 %, depending on the age and health of the patient. 
More severe cases of CAP are often associated with sec-
ondary bacteremia, where 30-day mortality is estimated 
to be as high as 20–48 % [3, 7–9]. Among all age groups, 
CAP is attributed to more than 10M physician visits, 
Abstract 
Purpose The burden of community-acquired pneumo-
nia (CAP) is not well described in the US Veterans Health 
Administration (VHA).
Methods CAP was defined as having a pneumonia diag-
nosis with evidence of chest X-ray, and no evidence of 
prior (90 days) hospitalization/long-term care. We calcu-
lated incidence rates of adult CAP occurring in inpatient 
or outpatient VHA settings in 2011. We also estimated the 
proportion of VHA CAP patients who were hospitalized, 
were readmitted within 30 days of hospital discharge, and 
died (any cause) in the year following diagnosis. Incre-
mental costs during the 90 days following a CAP diagnosis 
were estimated from the perspective of the VHA.
Results In 2011, 34,101 Veterans developed CAP (35,380 
episodes) over 7,739,757 VHA person-years. Median age 
of CAP patients was 65 years (95 % male). CAP incidence 
rates were higher for those aged ≥50 years. A majority of 
Veterans aged 50–64 (53 %) and ≥65 (66 %) years had ≥1 
chronic medical (moderate risk) or immunocompromis-
ing (high risk) condition. Compared to those at low-risk 
(healthy), moderate- and high-risk Veterans were >3 and 
>6 times more likely to develop CAP, respectively. The 
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64M days of restricted activity, and 600,000–1.1M hos-
pitalizations each year in the United States [10–13], with 
an estimated US annual cost of more than $17 billion [7]. 
As the population ages, the burden of CAP is expected to 
increase. Although previous studies have highlighted the 
burden of CAP in several settings, less is known about the 
burden of CAP in the US Veterans Health Administration 
(VHA) population. Given that increased incidence of CAP 
has been shown to be related to being both older and male 
[14], the Veteran population is a unique and ideal popula-
tion in which to measure both the clinical and economic 
burden of disease.
The VHA is the United States’ largest integrated health-
care system, providing care to 8.3 million Veterans every 
year, and is made up of more than 150 medical centers. 
These medical centers range in size and complexity from 
small, rural hospitals to tertiary care teaching facilities with 
academic medical center affiliations. In addition to VA hos-
pitals and medical centers, the VHA system encompasses 
nearly 1400 outpatient clinics, nursing homes, inpatient 
and outpatient mental health facilities, home-based care 
services, and other health services.
Study objective
We conducted a retrospective database analysis to calculate 
incidence rates of adult CAP occurring in inpatient or out-
patient VHA facilities in 2011. We also estimated the pro-
portion of VHA CAP patients who were hospitalized, were 
readmitted within 30 days of hospital discharge (if hospi-
talized), and died (any cause) in the year following diagno-
sis. Incremental costs that were accrued during the 90 days 
following a CAP diagnosis were estimated from the per-
spective of the VHA. Results describe both the overall and 




We retrospectively identified patients aged ≥18 years in 
the VHA Corporate Data Warehouse (CDW). CDW is 
composed of data from the entire VHA system, including 
both clinical and administrative data. Previous studies have 
noted that VHA users tend to be poorer, older, less edu-
cated, more likely to be unemployed or underemployed, 
more likely to be African American, and more likely to be 
in poorer health than either the general population or Vet-
erans who do not use the VHA system [15, 16]. To receive 
care in the VHA system, Veterans must qualify for health 
benefits based on their history of military service, current 
financial resources, and level of ‘service connectedness’. 
Medical conditions or disabilities are considered (partially 
or fully) ‘service connected’ if the illness or injury is deter-
mined to have occurred while in (or soon after) military 
service, have been a pre-existing condition aggravated by 
military service, or be related to a specific exposure while 
in service. We obtained study approval from the Veterans 
Affairs institutional review board and all data were de-iden-
tified prior to analysis.
Identification of community‑acquired pneumonia 
episodes
Pneumonia episodes began on the diagnosis (inpatient or 
outpatient) date of the first medical claim with any diag-
nosis of pneumonia (ICD9: 480–486, 487.0) from an inpa-
tient or outpatient setting from January 1 through Decem-
ber 31 of 2011. To be included, pneumonia episodes also 
had to have a medical claim with a procedure code for a 
chest X-ray (CPT code 71010–71035; ICD9-CM 87.4x) 
within 14 days before or after the initial diagnosis of pneu-
monia. To characterize episodes as community acquired, 
we excluded those with any claim for mechanical ventila-
tion, long-term care, hospitalization, pneumoconiosis, or 
wound care therapy in the 90 days prior to diagnosis [17]. 
CAP episodes with claims for treatment in the outpatient 
setting (including dialysis and chemotherapy infusion cent-
ers) in the 90 days prior to diagnosis were not excluded. 
CAP episodes ended on the date of the last observed medi-
cal claim with diagnosis for pneumonia that was followed 
by a minimum period of 90 days during which no medi-
cal claims with diagnoses of pneumonia were observed 
(“clean period”). This 90-day period was pre-specified as 
sufficient time to distinguish distinct CAP episodes and has 
been described previously [18]. An individual patient could 
have >1 CAP episode during the study period. Episodes 
that began at a late enough date that 90 days could not be 
observed between the last medical claim with a pneumonia 
diagnosis and the end of the study were included and cen-
sored at December 31, 2011. Episodes in which the patient 
died within the 90 days following the CAP episode were 
also included and were censored at the date of death. To 
determine whether or not a patient was hospitalized for 
CAP, we evaluated whether any inpatient claims (versus 
outpatient only) for CAP were present on the day of diag-
nosis or in the 30 days following the diagnosis.
Vital status
Mortality data were available from several sources within 
the VHA. The VHA Vital Status File includes mortality data 
from the inpatient Patient Treatment File, the Beneficiary 
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Identification & Records Locator System, Medicare, and 
the Social Security Administration death file. Data quality 
and accuracy from the combined data sources within the 
Vital Status File have been shown to be nearly as complete 
as the National Death Index.
Risk status
Patients were categorized into risk groups (low, moderate, 
or high) based on the presence of underlying immunocom-
promising or chronic medical conditions [19–21]. High 
risk was defined as having any immunocompromising con-
dition including: human immunodeficiency virus/acquired 
immune deficiency syndrome (HIV/AIDS); leukemia, 
lymphoma, Hodgkin’s Disease; generalized malignancy, 
excluding skin cancer; multiple myeloma; diseases requir-
ing treatment with immunosuppressive drugs including 
long-term corticosteroids or radiation therapy; nephrotic 
syndrome; chronic renal failure, including end-stage renal 
disease (ESRD); organ transplantation; cochlear implants, 
CSF leaks; sickle cell disease, functional or anatomic 
asplenia; and immune deficiency and other conditions con-
sistent with an immunocompromised state [19–21]. Mod-
erate risk was defined as the absence of immunocompro-
mising conditions but the presence of ≥1 chronic medical 
condition including: chronic heart disease, heart failure, 
cardiomyopathy, coronary artery disease; diabetes; chronic 
lung disease, COPD, asthma; liver disease or alcohol-
ism [19–21]. Low risk was defined as immunocompetent 
without any of the chronic medical conditions listed above 
[19–21].
Economic data
Economic data were extracted from the CDW Health Eco-
nomic Research Center (HERC) to estimate the incremen-
tal, average cost associated with developing CAP from the 
perspective of the VHA. The VHA is funded primarily by a 
Congressional appropriation; therefore, its utilization data 
do not assign costs or charges to specific patient encoun-
ters. To estimate the cost of medical services provided to 
VHA patients, we used average cost methods developed by 
HERC. Detailed descriptions of these methods, modeling 
assumptions, and comparisons to alternative costing meth-
ods have been published previously [22, 23]. The average 
cost method is used to model the cost of VHA services 
based on similar, hypothetical Medicare payments. HERC 
inpatient estimates represent the regionally adjusted, 
national average cost of similar Medicare hospital stays 
of Veterans in non-VA hospitals given VHA information 
about the Diagnosis Related Group, overall length of stay, 
and days in intensive care. HERC outpatient estimates rep-
resent the hypothetical, average Medicare reimbursement 
value, given the Current Procedure and Terminology codes 
assigned to a particular VHA outpatient visit.
Statistical analysis
Incidence rates (IRs) were constructed by dividing the 
number of CAP episodes that occurred in the VHA in 
2011 by the number of person-years (PYs) accrued in the 
VHA-enrolled population in that same year by age and risk 
groups. Incidence rate ratios (IRRs) and 95 % confidence 
intervals (CIs) were constructed by comparing IRs between 
various age and risk groups.
Among those who developed CAP, multivariable mod-
els were constructed to assess the effect of underlying risk 
status on the likelihood of initial hospitalization, 30-day 
readmission (among those who were hospitalized), and 
death, accounting for age and other sociodemographic fac-
tors. Because hospitalization for CAP was relatively com-
mon (45 %) and because logistic regression events are 
not well suited to predict common (> 10 %) events, log 
binomial regression models were used to estimate relative 
risk of hospitalization. To assess the relationship between 
patient-level factors and the proportion of patients who (1) 
were admitted to the hospital for CAP and then readmitted 
within 30 days of discharge for any cause and (2) died in 
the same year as the index CAP episode, logistic regression 
analyses were used.
For both log binomial and logistic regression analyses, the 
Likelihood Ratio (LR) Chi square test was used to determine 
improved statistical fit using a p value <.05 as significant 
model improvement. Additionally, for all models, each justi-
fiable interaction term was tested for statistical significance. 
Confounding was defined as a variable that changed the esti-
mated relative risk or odds ratio (OR) of a variable already in 
the model by ≥10–15 %. Any significant interaction terms 
or appreciable confounders remained in the final model. 
Because this was an exploratory burden of disease analysis, 
no adjustments for multiple comparisons were made. Thus, a 
two-sided alpha of .05 was used for all analyses.
Patients who were missing valid HERC data were 
excluded from cost analyses. For each patient with valid 
HERC data, estimates of inpatient and outpatient economic 
costs for each clinical encounter in the VHA system were 
developed for each primary episode of CAP and then aggre-
gated into per-patient, per-month (PPPM) costs for three time 
periods: (1) the 180 days prior to the development of CAP, 
(2) the 90 days following the diagnosis of CAP—including 
the diagnosis date (i.e., “CAP episode”), and (3) the 180 days 
after the (90-day) CAP episode. Given the skewed (non-
Gaussian) nature of health care cost data, differences between 
costs in the 180-day pre-CAP episode (baseline) periods were 
compared to the costs of both (1) the 90-day CAP episode 
and (2) the 180-days following the (90 day) CAP episode 
674 J. M. McLaughlin et al.
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using non-parametric Wilcoxon sign-rank tests. Finally, we 
assessed predictors of (90-day) CAP episode costs using a 
non-parametric quantile regression model.
Results
Patient characteristics and incidence 
of community‑acquired pneumonia
In 2011, 7,824,850 patients were enrolled in the VHA. 
Of which, 26, 33, 26, and 15 % were aged 18–49, 50–64, 
65–79, and ≥80 years, respectively. A majority of VHA 
patients aged 50–64 (53 %) and aged ≥65 years (66 %) 
had ≥1 chronic medical or immunocompromising condi-
tion that put them at increased risk for developing CAP. 
Twenty-three percent of all VHA patients aged ≥65 years 
had an immunocompromising condition (Fig. 1).
In 2011, after applying selection criteria (Fig. 2), 
34,101 adult VHA patients developed CAP (35,380 epi-
sodes) over 7,739,757 VHA person-years. Three percent 
of CAP patients had >1 CAP episode during 2011. Median 
age of CAP patients was 65 years (95 % male). Of those 
who developed CAP, most were white race (74 %) and 
Fig. 1  Proportion of all adults 
in the Veterans Health Admin-
istration at low, moderate, 
and high risk for developing 
community-acquired pneu-
monia by age group, 2011 
(n = 7,824,850). Low risk was 
defined as immunocompetent 
without chronic medical condi-
tions. Moderate risk was defined 
as immunocompetent with ≥1 
chronic medical condition. High 



























Fig. 2  Selection criteria
All VHA patients aged ≥18 years diagnosed with 
pneumonia (ICD-9 480-486, 487.0) in 2011 
n=65,564




Final Study Population of VHA patients aged ≥18 
years who developed community-acquired 
pneumonia (CAP) in 2011
n=34,101
Recieved mechanical ventiliation in prior 90 days
(n=374; <1%)
Was in long-term care in prior 90 days
(n=260; <1%)
Was hospitalized, recieved an IV antibiotic, or recieved 
treatment in a wound care facility in the prior 90 days
(n=6,310; 16%)
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non-Hispanic (97 %). Roughly half were married (47 %) 
and service connected (45 %). A majority were exempt 
from copayment (82 %), and had some type of supplemen-
tal insurance (63 %) (eTable 1). Age was strongly related to 
the proportion of patients who had supplemental coverage, 
as patients who were Medicare age-eligible (≥65 years) 
were much more likely to have supplemental coverage (18–
49: 30 %; 50–64: 40 %; 65–79: 86 %; ≥80: 87 %; p for 
interaction <.001).
CAP incidence rates were higher for those aged ≥50 
vs 18–49 years. Incidence rates among those aged 50–64 
and ≥65 years were similar. Compared to those at low risk, 
moderate- and high-risk patients were >3 and >6 times 
more likely to develop CAP, respectively (Fig. 3; Table 1). 
In addition, compared to patients without comorbid or 
immunocompromising conditions, patients with a his-
tory of diabetes, dementia, or chronic heart, cerebrovascu-
lar, lung, or liver disease were 3–14 times more likely to 
Fig. 3  Incidence rate (per 
100,000 person-years) of 
community-acquired pneumonia 
(CAP) by age and risk of devel-
oping cap in the Veterans Health 
Administration, 2011 (epi-
sodes = 35,380, n = 7,824,850; 
PYs = 7,739,757). PYs are 
person-years. Low risk was 
defined as immunocompetent 
without chronic medical condi-
tions. Moderate risk was defined 
as immunocompetent with ≥1 
chronic medical condition. High 
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Table 1  Incidence rate ratios (IRR) and 95 % confidence intervals (CI) for developing community-acquired pneumonia (CAP) by age group and 
risk of developing CAP in the Veterans Health Administration, 2011 (episodes = 35,380, n = 7,824,850; PYs = 7,739,757)
PYs Person-years and COPD chronic obstructive pulmonary disorder
* Low risk was defined as immunocompetent without chronic medical conditions. Moderate risk was defined as immunocompetent with ≥1 
chronic medical condition. High risk was defined as immunocompromised
† For each comorbidity category, low-risk patients (i.e., immunocompetent without chronic medical conditions) are the reference category. Each 
comorbidity category was defined as having any claim for the selected underlying comorbid condition, regardless of history of other comorbid or 
immunocompromising conditions













Aggregate risk for CAP*
 Low 1.00 1.00 1.00 1.00
 Moderate 3.24 (3.12, 3.35) 4.15 (4.11, 4.19) 4.83 (4.79, 4.87) 4.00 (3.95, 4.05)
 High 6.86 (6.76, 6.97) 7.44 (7.39, 7.49) 7.94 (7.97, 8.01) 6.32 (6.24, 6.40)
Select comorbidities†
 Heart Failure 11.6 (11.4, 11.8) 11.4 (11.3, 11.4) 14.0 (13.9, 14.1) 11.1 (11.0, 11.1)
 Coronary artery disease 4.55 (4.40, 4.69) 5.42 (5.38, 5.46) 6.09 (6.05, 6.13) 4.78 (4.73, 4.82)
 Stroke 4.50 (4.23, 4.77) 5.78 (5.72, 5.84) 7.86 (7.81, 7.91) 7.57 (7.52, 7.63)
 Diabetes 3.42 (3.32, 3.53) 4.35 (4.31, 4.38) 5.41 (5.37, 5.45) 4.77 (4.72, 4.82)
 COPD 7.57 (7.45, 7.68) 9.54 (9.50, 9.57) 12.2 (12.2, 12.2) 9.60 (9.55, 9.65)
 Asthma 4.49 (4.39, 4.59) 6.79 (6.73, 6.84) 9.08 (9.02, 9.14) 7.66 (7.57, 7.74)
 Chronic liver disease 4.43 (4.26, 4.59) 6.27 (6.22, 6.32) 9.30 (9.21, 9.38) 10.2 (10.1, 10.4)
 Alcoholism 3.01 (2.91, 3.11) 5.26 (5.22, 5.30) 8.78 (8.71, 8.84) 8.79 (8.66, 8.92)
 Dementia 3.52 (3.25, 3.79) 6.46 (6.36, 6.56) 8.53 (8.46, 8.60) 7.51 (7.46, 7.56)
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develop CAP, depending on the specific comorbid illness 
and age of the patient (Table 1). Patients with a history of 
heart failure (11–14 times more likely) or COPD (7–12 
times more likely) were especially more likely to develop 
CAP across all age groups (Table 1).
Clinical outcomes of community‑acquired pneumonia
Older CAP patients and those at moderate or high risk were 
more likely to be hospitalized and had higher mortality 
rates. The percentage of all adult CAP patients who were 
hospitalized was 45 %, ranging from 12 % (age 18–49 at 
low risk) to 57 % (age ≥65 at high risk). Among those 
who were hospitalized, average length of stay was 8 days 
(median 5 days) and 16 % were readmitted (any cause) 
within 30 days of discharge. Among CAP patients, same-
year, all-cause mortality rates ranged from 1 % (age 18–49 
at low risk) to 36 % (age ≥65 at high risk) (Table 2).
Of the VHA patients who developed CAP in 2011, the 
vast majority aged 50–64 (84 %) and ≥65 (91 %) years had 
some type of underlying immunocompromising or chronic 
medical condition (eTable 2). Immunocompromising con-
ditions were composed mainly of chronic renal disease or 
solid organ cancer. Prevalent chronic medical conditions 
among those who developed CAP included history of 
heart failure, coronary artery disease, diabetes, and COPD. 
Although not common among those aged ≥65 years, 
among those aged 50–64 years, chronic liver disease and 
alcoholism were prevalent among those who developed 
CAP in the VHA (eTable 2).
Results of multivariable modeling showed that even 
after adjustment for age and other sociodemographic fac-
tors, compared to patients at low risk, patients at moderate 
risk were 1.85 (95 % CI 1.71, 1.98) times more likely to be 
hospitalized for CAP, 1.47 (95 % CI 1.19, 1.80) times more 
likely to be readmitted (any cause) within 30 days if they 
were hospitalized, and 1.51 (95 % CI 1.34, 1.71) times as 
likely to die in the same year of the CAP episode. High-risk 
patients (compared to low-risk patients) were 2.11 (95 % 
CI 1.96, 2.27) times more likely to be hospitalized for CAP, 
1.90 (95 %CI 1.54, 2.33) times more likely to be readmit-
ted (any cause) within 30 days if they were hospitalized, 
and 3.75 (95 % CI 3.32, 4.23) times as likely to die in the 
same year of the CAP episode (eTable 3). Other factors 
associated with hospitalization for CAP (p < .05) included 
increasing age, being unmarried, not having service con-
nection, not having supplemental health insurance, and 
being exempt from copayment. Another factor associated 
with 30-day readmission after a CAP hospitalization (any 
cause) (p < .05) was not having supplemental health insur-
ance. Other factors associated with mortality in the same 
year of developing CAP (p < .05) included increasing age, 
not having supplemental health insurance, and being hospi-
talized for the CAP episode (eTable 3).
Economic impact of community‑acquired pneumonia
Among all VHA patients who developed CAP in 2011, 
52 (<0.2 %) patients were missing valid HERC cost data 
and were excluded from cost analyses. Average total per-
patient, per-month (PPPM) costs increased from $1,020 
(median $381) during the 180-day period before the CAP 
episode to $7,154 (median $3,174) during the 90-day CAP 
episode period (p < .0001) (Fig. 4). In the 180 days fol-
lowing the 90-day CAP episode, PPPM costs declined to 
$1488 (median $347), but average PPPM costs (though 
not median PPPM costs) still remained higher than the 
pre-CAP episode period. However, if patients without 
adequate post-CAP episode follow-up data were excluded 
(i.e., patients who died during 2011), both mean and 
median PPPM costs during the 180-day post-CAP period 
were higher (median $1,401 vs $410; p < .0001) than that 
in the 180-day, pre-CAP period. These trends were con-
sistent across all age/risk strata and were driven primarily 
Table 2  Proportion of community-acquired pneumonia (CAP) Patients who were hospitalized for CAP, readmitted (any cause) within 30-days 
of hospital discharge, or died in the same year as the CAP event by risk status and age Group, 2011 (n = 34,101)
* Low risk was defined as immunocompetent without chronic medical conditions. Moderate risk was defined as immunocompetent with ≥1 
chronic medical condition. High risk was defined as immunocompromised




Died Hospitalized 30-Day 
all-cause 
readmission





 18–49 (n = 3,557) 234 (12) 23 (10) 21 (1) 315 (26) 40 (13) 32 (3) 159 (42) 30 (19) 37 (10)
 50–64 (n = 12,962) 409 (20) 32 (8) 85 (4) 3,072 (43) 475 (15) 603 (8) 2,019 (55) 409 (20) 978 (27)
 65–79 (n = 10,515) 230 (25) 24 (10) 82 (9) 2,451 (46) 348 (14) 786 (15) 2,371 (55) 433 (18) 1,353 (32)
 ≥80 (n = 7,067) 302 (45) 40 (13) 189 (28) 1,798 (56) 245 (14) 1,010 (31) 1,905 (60) 278 (15) 1,309 (41)
 All Ages 1,175 (21) 119 (10) 377 (7) 7,636 (45) 1,108 (15) 2,431 (14) 6,454 (56) 1,150 (18) 3,677 (32)
677Clinical and economic burden of CAP…
1 3
by increases in the cost of inpatient care (eFigure 1). If we 
assume that these increases in cost from the 180-day, pre-
CAP baseline period stem from CAP- and CAP sequelae-
related care, the excess economic burden attributable to 
each CAP episode in the (1) 90 days during the CAP epi-
sode and (2) 180 days following the (90-day) CAP episode 
was $18,399 and $2,804, respectively. Thus, for the 35,380 
CAP episodes that occurred in 2011, the excess economic 
burden was estimated to be $750.2 M ($415.1 M for those 
aged ≥ 65 years) during the 90-day CAP episode period 
and the period of 180 days following the episode—driven 
mainly by an estimated $719.9 M in additional inpatient 
expenditures (eTable 4). Final quantile regression modeling 
showed that increasing age, black race (compared to white 
race), being unmarried, having 50–100 % service connec-
tion, not having supplemental insurance, having underlying 
comorbid or immunocompromising conditions, and being 
hospitalized were all related to significantly higher median 
CAP episode VHA costs (eTable 5).
Discussion
Community-acquired pneumonia remains a signifi-
cant health problem in the VHA, with >35,000 episodes 
(according to our definition) occurring within the VHA 
system in 2011 alone. These CAP episodes accounted for 
an estimated $750 M ($415 M for those aged ≥ 65 years) 
worth of additional VHA annual medical costs—the large 
majority of which ($720 M; 96 %) were due to additional 
expenditures related to hospitalization and other inpatient 
services. It is also worth noting that, among patients who 
survived a CAP episode and had sufficient post-episode 
follow-up, patient health care costs were not only sig-
nificantly higher during the CAP episode, but they also 
remained higher during the 6 months following the (90-
day) CAP episode as well.
This significant burden of CAP persists despite the 
fact that VHA patients have pneumococcal polysaccha-
ride vaccination coverage that is notably better than both 
(1) the general, non-VA population and (2) Veterans who 
do not participate in VHA [24]. At the time of this study, 
only 23-valent pneumococcal polysaccharide vaccine was 
approved for routine use in adults. Since this study was 
conducted, however, 13-valent pneumococcal conjugate 
vaccine (PCV13) was approved for use in adults aged 
≥50 years on December 30, 2011 [25], and subsequently 
recommended for routine use in all adults aged ≥65 years 
by ACIP in September 2014 [26]. CDC estimated that 









180 days before CAP episode 90 days during CAP episode 180 days after CAP episode
Average PMPM Costs for Each Time Period
total inpatient outpatient
Fig. 4  Average per-patient, per-month (pppm) costs before, during, 
and after the development of community-acquired pneumonia (CAP) 
among Veterans Health Administration-eligible persons who CAP, 
2011 (n = 34,049). 52 of 34,101 patients were missing valid eco-
nomic data from the HERC dataset. The “CAP episode” was defined 
as the 90 days following the diagnosis of CAP—including the diag-
nosis date. Data were adjusted to account for local variations in costs
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adults aged ≥65 years are caused by PCV13 serotypes and 
are potentially preventable with the use of PCV13 in this 
population.” [26–28].
The burden of CAP among VHA patients was especially 
high among those aged ≥50 years and among those who 
had underlying chronic medical or immunocompromising 
conditions. From the VHA perspective, incidence of CAP 
among those aged 50–64 years was comparable to those 
over age 65. This observation, however, must be interpreted 
in the context of the VHA population. Namely, that nearly 
all patients aged ≥65 years are dually eligible for Medicare 
insurance. Therefore, some elderly VHA patients may seek 
care for CAP outside of the VHA system with health insur-
ance coverage provided by Medicare and, subsequently, 
would not have been captured in our analysis.
In addition to age, risk status was also related to CAP 
burden. Specifically, compared to those at low risk, mod-
erate- and high-risk patients were >3 and >6 times more 
likely to develop CAP, respectively. A more granular look 
at specific comorbid illnesses revealed that, compared to 
patients without comorbid or immunocompromising con-
ditions, patients with a history of diabetes, dementia, or 
chronic heart, cerebrovascular, lung, or liver disease were 
3–14 times more likely to develop CAP. This is espe-
cially worth noting, given that half of VHA patients aged 
≥50 years and nearly two-thirds of VHA patients aged 
≥65 years had ≥1 chronic medical or immunocompro-
mising condition. Taken together, these data underscore 
the importance of CAP prevention and the management of 
modifiable risk factors among a subpopulation at especially 
high risk of developing CAP. Indeed, not only did nearly 
two-thirds of all patients eligible for VHA benefits aged 
≥65 years have ≥1 chronic medical or immunocompro-
mising conditions, but of those who developed CAP, 91 % 
had ≥1 chronic medical or immunocompromising condi-
tion. The most prevalent chronic (non-immunocompromis-
ing) medical conditions among those who developed CAP 
included history of heart failure, coronary artery disease, 
diabetes, and COPD. Although not common among those 
aged ≥65 years, among those aged 50–64 years, chronic 
liver disease and alcoholism were prevalent among those 
who developed CAP in the VHA. Immunocompromising 
conditions were composed mainly of chronic renal disease 
or solid organ cancer. Although not typically included in 
the list of conditions thought to lead to increased risk of 
CAP [19–21], a history of either stroke or dementia lead 
to >5 times increased risk among those aged 50–64 years 
and >7 times increased risk among those aged ≥65 years 
compared to patients without comorbid or immunocompro-
mising conditions.
In addition to risk status predicting the development 
of CAP, risk status—independent of age and other demo-
graphic characteristics—was strongly associated with rates 
of hospitalization, 30-day readmission (among those who 
were hospitalized), and death. Thus, not only were patients 
with underlying comorbid or immunocompromising con-
ditions more likely to develop CAP, but also, if they did 
ultimately develop CAP, moderate- and high-risk patients 
were more likely to be hospitalized and had higher mor-
tality rates. For example, results from this study showed 
that, among all adult patients eligible for VHA care, only 
21 % of low-risk patients were hospitalized for CAP, how-
ever, that number climbed to 45 % hospitalized among 
moderate-risk patients and 56 % hospitalized among high-
risk patients. Same year, all-cause mortality rates showed 
a similar trend, with 7, 14, and 32 % of low-, moderate-, 
and high-risk patients, respectively, dying in the same year 
they developed CAP. Patients with underlying comorbid or 
immunocompromising conditions also had higher health 
care costs. Compared to low-risk patients, median (90-
day) CAP episode costs for moderate and high-risk patients 
were $901 (95 %CI $461, $1,341) and $4,659 (95 %CI 
$4,182, $5,135) higher, respectively.
Previous studies have suggested that, compared to the 
general US population or Veterans who do not use the VHA 
system, VHA patients report poorer physical and mental 
health and have more underlying chronic health conditions. 
[15, 16] Results from this study confirm these findings, as 
data from our report showed that a higher proportion of 
VHA patients had underlying immunocompromising or 
chronic medical conditions compared to the general pri-
vately insured population [21]. These results, combined 
with the fact that patients at moderate or high risk for 
developing CAP were more likely to be hospitalized and 
had higher mortality rates, suggest that a focus on CAP 
prevention and the management of modifiable risk factors 
among those with comorbid or immunocompromising con-
ditions may be especially important in the VHA system. 
These data are compounded by evidence, both in this study 
and elsewhere [14], demonstrating that the incidence of 
CAP is related to being both older and male—characteris-
tics typical of the Veteran population.
Limitations
This study was not without limitations. Primarily, the man-
ner in which we defined an episode of CAP was based on 
an algorithm of diagnostic and procedural claims. While 
this definition has been used before [21, 29, 30], diagnos-
tic codes are not always accurate. Specifically, we could 
only assess whether a chest X-ray was performed within 
2 weeks of diagnosis—whether or not the chest X-ray 
was conclusive of pneumonia was unknown. Another 
limitation is the inability to always accurately distinguish 
between community-acquired and health care-associated 
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pneumonia. Our definition of community-acquired pneu-
monia excluded patients that had any inpatient encounters 
in the prior 90 days. This definition is likely conservative 
and may underestimate the incidence of CAP, as other 
studies have used 7-day [29] or 14-day [30] windows 
(rather than 90 days) to distinguish between community-
acquired and health care-associated pneumonia. Finally, 
although this study captured the burden of CAP from the 
perspective of the VHA—it likely underestimated the true 
burden of CAP for all VHA patients. Specifically, given 
that many VHA patients (especially those aged ≥65 years 
who are eligible for Medicare) are dually eligible for sup-
plemental insurance, it is likely that some VHA patients 
sought care for CAP outside of the VHA system and would 
not have been captured in our analysis [31–34]. As such, 
our incidence rates should be interpreted with caution and 
only in this context. In the same vein, it is also possible; 
however, that we classified some health care-associated 
cases of pneumonia as community-acquired—where prior 
hospitalization or long-term did occur in the 90 days prior 
to a pneumonia diagnosis, but it occurred in a non-VHA 
setting.
Conclusion
In 2011, >35,000 CAP episodes occurred in the VHA 
(18,375 CAP episodes among those aged ≥65 years), 
despite historically high coverage with pneumococcal poly-
saccharide vaccine (>80 %). [24] Economic data revealed 
that CAP episodes were associated with a notable increase 
in cost during the 90-day CAP episode period and could 
account for as much as $750M ($415M for those aged 
≥65 years) in additional annual medical costs—the large 
majority of which ($720M; 96 %) were due to additional 
expenditures related to hospitalization and other inpatient 
services. Moreover, the true burden among VHA patients 
was likely higher—perhaps considerably so—given that 
many patients have supplemental insurance (namely 
Medicare) and may have sought treatment for CAP out-
side of the VHA system. In addition, more than half of 
all VHA patients aged ≥50 and nearly two-thirds of all 
VHA patients aged ≥65 years had ≥1 chronic medical or 
immunocompromising conditions, and these conditions 
were associated with several fold higher risk of developing 
CAP. In summary, a renewed focus on CAP prevention and 
the management of modifiable risk factors in the VHA is 
important. Prevention is especially important among older 
patients and patients with underlying comorbid or immuno-
compromising conditions, as these patients were not only 
more likely to develop CAP, but were also more costly and 
more likely to be hospitalized, readmitted within 30 days, 
and die if they did develop CAP.
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